Business Wire

IFF to Share Strong Progress on Frutarom Combination at Barclays Global Consumer Staples Conference

Del

Regulatory News:

International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, today will provide an update at the Barclays Global Consumer Staples Conference on the Company’s progress on its previously announced combination with Frutarom to create a global leader in taste, scent and nutrition.

Andreas Fibig, IFF Chairman and Chief Executive Officer, and Richard O’Leary, IFF Executive Vice President and Chief Financial Officer will present today at 11:15 a.m. ET. A live audio webcast and replay will be available at ir.iff.com.

“The combination of IFF and Frutarom is truly unique and compelling as it positions us as a global leader in taste, scent and nutrition,” said Andreas Fibig, Chairman and CEO. “We are excited that this enables us to have a stronger product offering, greater exposure to fast-growing customers and broader access to attractive adjacencies. We believe this will translate into accelerated financial performance as a combined company, with robust top and bottom-line growth.

“We have made significant progress planning for the integration of our two companies, and our accelerated timeline to close this transaction in early October, pending all remaining antitrust approvals, is a true testament to the hard work and integration planning efforts underway. On this strong foundation, we believe that we will unlock significant long-term value for our shareholders.”

Combination will enrich IFF’s portfolio with a stronger product offering, greater exposure to fast-growing customers and broader access in attractive adjacencies

  • Creates a differentiated portfolio with an increased focus on naturals and health and wellness as well as more comprehensive solutions
  • Enhances IFF’s exposure to the fast-growing small- and mid-sized customers, including private label
  • Provides opportunities to expand into attractive and fast-growing categories, such as savory solutions, natural colors, natural food protection and health ingredients

Expects to accelerate financial growth rates as a combined company

  • Increases average sales growth targets to 5-7%, on a currency neutral and pro-forma basis, for 2019 to 2021 period
  • Updates average currency neutral adjusted cash EPS growth to 10% or greater for 2019 to 2021 period
  • Anticipates cost synergies of $145 million by rationalizing procurement, optimizing global footprint and streamlining overhead expenses by the third full year after the completion of the merger
  • Prioritizes repayment of debt and anticipates to be less than 3X net debt to EBITDA in 18-24 months to retain investment grade rating

Strong progression towards transaction completion

  • Frutarom shareholders approved transaction with IFF by a majority of ~95%
  • On-track with all antitrust filings submitted and approvals received in 6 of 8 jurisdictions
  • Close expected in early October pending remaining antitrust approvals
  • IFF and Frutarom had a strong start to 2018 with robust top and bottom-line performances

Meet IFF
International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in beloved foods and beverages, iconic fine fragrances and household goods, as well as indispensable personal and skincare products. Our 7,300 team members globally take advantage of leading consumer insights, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products. Learn more at www.iff.com, Twitter, Facebook, Instagram, and LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding IFF’s or Frutarom’s expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management and statements containing the words such as “anticipate,” “approximate,” “believe,” “plan,” “estimate,” “expect,” “project,” “could,” “should,” “will,” “intend,” “may” and other similar expressions, are forward-looking statements. Statements in this press release concerning IFF’s or Frutarom’s 2018 outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items, and product or services line growth, together with other statements that are not historical facts, are forward-looking statements that are estimates reflecting management’s best judgment based upon currently available information. IFF can give no assurance that its estimates will be attained. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. Forward-looking statements speak only as of the date(s) indicated in this press release.

IFF’s results may be materially affected by factors such as, but not limited to: (1) the inability to obtain required regulatory approvals for the Frutarom acquisition (the “acquisition”), the timing of obtaining such approvals and the risk that such approvals may result in the imposition of adverse conditions; (2) the risk that a closing condition to the acquisition may not be satisfied on a timely basis or at all or that the acquisition may not close for any reason; (3) uncertainties as to access to financing on a timely basis and on reasonable terms or at all; (4) the impact of IFF’s proposed financing on its liquidity and flexibility to respond to other opportunities; (5) whether the acquisition will have the accretive effect on IFF’s earnings or cash flows that it expects; (6) the inability to obtain, or delays in obtaining, cost savings and synergies from the acquisition; (7) business and operations integration costs and difficulties; (8) unexpected costs, liabilities, charges or expenses relating to the acquisition; (9) adverse effects on IFF’s stock price resulting from the acquisition; (10) adverse effects on business relationships or competitive responses resulting from the acquisition; (11) the inability to compete in the markets in which IFF operates; (12) the inability to retain existing and win new customers; (13) the inability to develop and introduce new products that appeal to IFF’s customers; (14) disruptions in IFF’s manufacturing or supply chain; (15) the inability to obtain raw materials of quality, on cost-effective terms or at all, including citral; (16) the inability to successfully implement IFF’s Vision 2020 strategy, including its acquisition strategy; (17) the risk of information technology failure or interruption, of information security breaches, and risks relating to intellectual property rights; (18) adverse currency fluctuations or devaluations; (19) the regulatory, political, economic, social and other risks of international operations, including in emerging markets; (20) adverse changes in customer preferences or a decrease in consumer spending; (21) the inability to attract or retain key personnel; (22) the inability to realize the benefits of IFF’s cost and productivity initiatives; (23) the cost and difficulty of complying with, and risk of adverse changes to, domestic, foreign and international laws, regulations and rules, including regarding taxation; (24) volatility and increases in the price of raw materials, energy and transportation; (25) price realization in a rising input cost environment; and (26) the risk of adverse legal or regulatory proceedings. For a discussion of risks and important factors that could cause actual results to differ from expectations, projections and forward-looking statements, see the risks and other factors and information in IFF's filings with the Securities and Exchange Commission, including IFF’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings available on IFF’s website (www.iff.com). New risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risks on IFF’s business. IFF disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

In this press release we provide forward-looking CAGR and net debt to EBITDA amounts in the form of guidance. This guidance is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort because of the unpredictability of the amounts and timing of events affecting the items we exclude from non-GAAP measures. For example, acquisition-related costs, restructuring and other charges, net, and integration costs are all impacted by the timing and size of potential future actions, which are difficult to predict. In addition, from time to time, we exclude certain items that occur infrequently, which are also inherently difficult to predict and estimate. It is also difficult to predict the tax effect of the items we exclude and to estimate certain discrete tax items, like the resolution of tax audits or changes to tax laws. As such, the costs that are being excluded from non-GAAP guidance are difficult to predict and a reconciliation or a range of results could lead to disclosure that would be imprecise or potentially misleading. Material changes to any one of the exclusions could have a significant effect on our guidance and future GAAP results.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any security and may not be relied upon in connection with the purchase or sale of any security. Any such offer would only be made by means of formal offering documents, the terms of which would govern in all respects. You are cautioned against using this information as the basis for making a decision to purchase any security.

You should not rely exclusively on this press release as the basis upon which to make an investment decision. The information in this press release is provided to you as of the dates indicated and IFF does not intend to update the information after its distribution, even in the event that the information becomes materially inaccurate. Certain information contained in this press release includes calculations or figures that have been prepared internally and have not been audited or verified by a third party. Use of different methods for preparing, calculating or presenting information may lead to different results and such differences may be material. In addition, in all cases where historical performance is presented, please note that past performance is not a reliable indicator of future results and should not be relied upon as the basis for making an investment decision.

These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation.

Contact information

International Flavors & Fragrances Inc.
Michael DeVeau, 212-708-7164
VP, Corporate Strategy, Investor Relations & Communications
Michael.DeVeau@iff.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting23.4.2019 08:38:00 CESTPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, today announced that new data from its lead development program, VTX-801 a novel investigational gene therapy for WD, and VTX-803, Vivet’ novel therapeutic in development for the treatment of PFIC3, have been accepted for oral presentation during the ASGCT 22nd Annual Meeting, April 29 - May 2, 2019 in Washington, D.C., USA. Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA will present data from a recently completed study, validating in WD mice the use of fecal excretion of IV-injected 64copper as a pharmacodynamic endpoint in the VTX-801 Phase I/II trial currently under preparation. These data are the first demonstration of copper homeostasis restoration with 64Copper in an animal model of WD through the delivery of a single, intravenous administration of

Transphorm Centers on the Simplicity and Reliability of High Voltage GaN Application Development at PCIM 201923.4.2019 08:00:00 CESTPressemelding

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V and 900 V gallium nitride (GaN) semiconductors—today shared a glimpse into its 2019 PCIM Europe showcase. Located in Hall 9 Booth 519, it centers on three key points to help conference attendees better understand Transphorm’s high voltage GaN value proposition: Reliability: Design with confidence when using Transphorm’s high quality, high reliability (Q+R) GaN transistors. Drivability: Pair Transphorm’s devices with off-the-shelf drivers, for easing drivability. Simplicity: Experience simpler designs due to minimal external gate drive circuitry along with standard packages, such as TO-220, TO-247, and PQFN, with well-known thermal management techniques. “At PCIM, you’ll see the culmination of Transphorm’s innovation along with its measurable impact on low volume as well as high volume customer applications,” said Philip Zuk, Vice President, Technical Marke

PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC23.4.2019 07:00:00 CESTPressemelding

A seminar titled “2H19 PV Market Outlook and Forecast” will be held in Shanghai on June 3, one day prior to SNEC, to discuss global supply chain market outlook in the second half of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005391/en/ 2019 Module Prices and Demand Forecast. (Photo: Business Wire) Held by PV InfoLink, a leading solar market intelligence provider, the seminar will bring together PV manufacturers, developers, EPC, and investors to explore major issues revolving the industry and help participants gain valuable insights for navigating the expanding solar market. PV InfoLink has invited Chinese major companies, including Jinko, Longi, and GCL-Si, to discuss impact of China’s transition to a subsidy-free market. This year, China’s demand will revive later than usual due to policy uncertainty. Moreover, Japan and India, China’s two major trading partners, saw weakening demand after the end of f

JPND Launches Updated Research and Innovation Strategy23.4.2019 06:45:00 CESTPressemelding

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative 1 has launched its updated global Research and Innovation Strategy (RIS) , to provide a unified framework for the support of world class research into neurodegenerative diseases. Neurodegenerative diseases are one of the world’s leading medical and societal challenges and there are now expected to be 50 million people worldwide suffering from Alzheimer’s disease and related disorders. Globally, these numbers show no signs of abating, and it is estimated that by 2050 in Europe alone, the total direct and informal care costs for Alzheimer’s and Parkinson’s disease will exceed €350 billion annually.2 JPND is the first and largest collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases. JPND’s ultimate goal is to accelerate the discovery of a cure and to enable early diagnosis for early personalised treatments. In the meantime, it is essential to implement

Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer22.4.2019 15:00:00 CESTPressemelding

Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and University of California San Diego, Moores Cancer Center (USA) (Razelle Kurzrock), aimed to expand precision oncology to patients with advanced solid tumors that progressed after treatment with standard therapies. For

PPG Advances Sustainability to Protect and Beautify the World22.4.2019 14:13:00 CESTPressemelding

PPG (NYSE:PPG) today published its 2018 Sustainability Report, detailing the company’s performance and progress against its 2025 sustainability goals that contribute to its purpose and promise: WE PROTECT AND BEAUTIFY THE WORLD™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190422005156/en/ PPG highlights progress against key economic, environment and social goals in its 2018 Sustainability Report. (Graphic: Business Wire) Last year, PPG embedded additional sustainable practices into its operations, introduced new sustainably advantaged products for customers, achieved a record low in injury cases across the company, advanced its global community engagement initiatives, and further advanced its diversity and inclusion efforts. The report is available at sustainability.ppg.com. “Our dedicated workforce continues to drive sustainability deeper into our global operations,” said Michael H. McGarry, PPG chairman and chief execu